Download
1 / 1
10 likes | 80 Views
**. **. a. b. 50. 0. 30. -5. 25. 40. -10. 20. -15. 30. Ascites volume (mL). Body weight gain (g/7 days). -20. Food intake (g). 15. 20. -25. 10. -30. 10. 5. *. -35. *. 0. 0. DW. SB242084 5 mg/kg, p.o. Rikkunshito 500 mg/kg, p.o. DW. SB242084 5 mg/kg, p.o.
E N D
** ** a b 50 0 30 -5 25 40 -10 20 -15 30 Ascites volume (mL) Body weight gain (g/7 days) -20 Food intake (g) 15 20 -25 10 -30 10 5 * -35 * 0 0 DW SB242084 5 mg/kg, p.o. Rikkunshito 500 mg/kg, p.o. DW SB242084 5 mg/kg, p.o. Rikkunshito 500 mg/kg, p.o. DW SB242084 5 mg/kg, p.o. Rikkunshito 500 mg/kg, p.o. Day 7 Day 6 d c 600 500 ** 400 Plasma CRP (mg/mL) 300 200 100 0 DW SB242084 5 mg/kg, p.o. Rikkunshito 500 mg/kg, p.o. e Supplemental Figure 1 Effects of daily oral administration of the 5-HT2cR antagonist SB242084 and rikkunshito on food intake, weight, ascites volume and plasma CRP.SB242084 and rikkunshito increased 48 hour-food intake (a) and inhibited weight loss (b) in tumor-bearing rats on day 7. (c) No change in ascites volume was observed. (d) Rikkunshito decreased plasma CRP level in tumor-bearing rats. (e) Rikkunshito increased muscle weight in tumor-bearing rats on day 7. Results are expressed as mean ± SE. (n=6-8). ** P < 0.01. DW: distilled water 2.0 DW Rikkunshito 500 mg/kg, p.o. 1.5 ** Weight (g) 1.0 * 0.5 0.0 Gastroc. muscle Tibialis muscle
